{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.4","upperLimit":"12.3","value":"11.9"}]}],"title":"IRC assessed, n=88"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.6","upperLimit":"12.3","value":"12.0"}]}],"title":"Investigator assessed, n=103"}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"}],"units":"Participants"}],"description":"Time to response is defined as the time from randomization until the first documented evidence of complete response (all detectable tumor has disappeared) or partial response (a \\>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the Baseline sum) (whichever status was recorded first).","dispersionType":"95% Confidence Interval","groups":[{"description":"Pazopanib 800 mg (tablets) administered orally once a day","id":"OG000","title":"Pazopanib 800 mg"}],"paramType":"MEDIAN","populationDescription":"ITT Population. Only participants with a complete or partial response were analyzed. Only results for pazopanib are given because there were not enough placebo responders. The different number of participants analyzed is due to differences in clinical judgement, measurement, and the selection of target lesions.","reportingStatus":"POSTED","timeFrame":"Randomization until CR or PR (assessed for up to 2 years)","title":"Time to Response as Assessed by an Independent Review Committee (IRC) and the Investigator","type":"SECONDARY","unitOfMeasure":"weeks"}